New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
08:21 EDTRHHBY, VVUS, ARNA, OREX, GSKU.S. market gets wave of new weight loss drugs, FT reports
The U.S. market has had only one prescription weight loss drug for several years, Roche’s (RHHBY) Xenical, which is also sold over-the-counter by GlaxoSmithKline (GSK) as Alli, but that drug has recently been joined by Vivus' (VVUS) Qsymia and Arena (ARNA) is set to launch Belviq shortly, reported Financial Times. Orexigen (OREX) is also preparing to re-submit its Contrave weight loss drug for a new regulatory review. The report on the resurgence of weight loss drug development noted that Vivus' CEO foresees the potential for using direct-to-consumer advertising and a larger scale sales force to market Qsymia, which would likely require a big pharma partner. Reference Link
News For VVUS;ARNA;OREX;GSK;RHHBY From The Last 14 Days
Check below for free stories on VVUS;ARNA;OREX;GSK;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2014
06:13 EDTGSKGlaxoSmithKline's malaria vaccine candidate accepted for EU regulatory review
Subscribe for More Information
06:13 EDTRHHBYRoche reaffirms outlook for 2014
Subscribe for More Information
06:12 EDTRHHBYRoche reports 1H core EPS CHF 7.57 vs. CHF 7.58 last year
Subscribe for More Information
July 23, 2014
09:33 EDTGSKGlaxoSmithKline reports record Promacta/Revolade Q2 revenue of $92M
Subscribe for More Information
09:17 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
09:08 EDTRHHBYUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
07:19 EDTGSKGenmab reports Q2 Arzerra net sales GBP 12.8M
Subscribe for More Information
07:12 EDTGSKGlaxoSmithKline lowers 2014 core EPS outlook to 'similar' to 2013
GSK now expects 2014 core EPS to be "broadly similar" to 2013 versus previous expectations of 4%-8% growth. It added, "Given impact of recent sustained strength of Sterling on free cash flow, share repurchases over balance of 2014 likely to be immaterial."
07:09 EDTGSKGlaxoSmithKline reports Q2 core EPS down 12% to 19.1p
Subscribe for More Information
07:09 EDTGSKMylan wins restraining order against Apotex for generic version of GSK's Paxil
Subscribe for More Information
July 22, 2014
09:55 EDTGSKLupin, private equity funds weigh bids for GSK's older drugs, Reuters reports
Subscribe for More Information
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
10:31 EDTOREXHigh option volume stocks:
High option volume stocks: EZPW LCI STLD SIAL FL OREX CROX NIHD EXTR BBT
08:11 EDTARNAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
07:11 EDTRHHBY, GSKInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTRHHBYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
07:18 EDTGSKMylan wins motion to enjoin GlaxoSmithKline from production of generic product
Subscribe for More Information
06:23 EDTGSKGlaxoSmithKline admits to bribing Chinese officials in 2001, FT reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use